US FDA Revokes Emergency Use of Anti-malarial Drug HCQ Championed by Trump for Covid-19

  • The FDA said its decision is based on new information, including clinical trial data results, that have led it to conclude that the drug may not be effective to treat COVID-19 and its potential benefits do not outweigh its potential risks.

Read full article: